TMS Co., Ltd Logo

TMS Co., Ltd

Develops small molecule drugs from natural compounds for the global pharmaceutical market.

4891 | T

Overview

Corporate Details

ISIN(s):
JP3544960002
LEI:
Country:
Japan
Address:
府中市府中町一丁目9番地京王府中1丁目ビル11階
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

TMS Co., Ltd. is a biotechnology company engaged in the research, development, manufacture, and sale of pharmaceuticals, quasi-drugs, drug substances, and medical devices. The company focuses on developing small molecule drug candidates derived from natural compound libraries, collaborating with academic institutions to bridge scientific discoveries with the global pharmaceutical market. Its research includes the development of SMTPs (Small Molecule Therapeutic Products), which have shown potential in promoting thrombolysis, suppressing inflammation, and providing antioxidation.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-10-15 08:41
Report Publication Announcement
確認書
Japanese 7.9 KB
2025-10-15 08:40
Interim Report
半期報告書-第22期(2025/03/01-2025/12/31)
Japanese 212.5 KB
2025-05-30 03:20
Post-Annual General Meeting Information
臨時報告書
Japanese 27.5 KB
2025-05-30 03:18
Registration Form
確認書
Japanese 7.9 KB
2025-05-30 03:17
Governance Information
内部統制報告書-第21期(2024/03/01-2025/02/28)
Japanese 21.1 KB
2025-05-30 03:15
Annual Report
有価証券報告書-第21期(2024/03/01-2025/02/28)
Japanese 2.9 MB
2025-04-09 09:05
Regulatory News Service
臨時報告書
Japanese 19.9 KB
2025-03-14 07:58
Prospectus
有価証券届出書(組込方式)
Japanese 407.4 KB
2025-02-28 07:37
Legal Proceedings Report
臨時報告書
Japanese 18.5 KB
2025-02-06 09:01
Regulatory News Service
臨時報告書
Japanese 19.1 KB
2024-10-15 08:18
Report Publication Announcement
確認書
Japanese 7.9 KB
2024-10-15 08:15
Interim Report
半期報告書-第21期(2024/03/01-2025/02/28)
Japanese 176.1 KB
2024-07-12 08:14
Regulatory News Service
確認書
Japanese 7.9 KB
2024-07-12 08:12
Quarterly Report
四半期報告書-第21期第1四半期(2024/03/01-2024/05/31)
Japanese 125.8 KB
2024-05-29 03:27
Registration Form
確認書
Japanese 7.9 KB

Automate Your Workflow. Get a real-time feed of all TMS Co., Ltd filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for TMS Co., Ltd

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for TMS Co., Ltd via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
ALK-Abelló Logo
Develops allergy immunotherapy (AIT) and emergency treatments for severe allergies.
Denmark ALK
Alkaloid AD Logo
Manufactures pharmaceuticals, cosmetics, and herbal products for professionals and consumers.
North Macedonia ALK
Alkermes plc. Logo
Develops medicines for CNS disorders like schizophrenia, bipolar, and sleep disorders.
United States of America ALKS
Allarity Therapeutics, Inc. Logo
Develops personalized cancer drugs using a diagnostic platform to predict patient response.
United States of America ALLR
ALLERGY THERAPEUTICS PLC Logo
Develops innovative, aluminum-free allergy immunotherapy vaccines for the European market.
United Kingdom AGY
Alligator Bioscience Logo
Develops immuno-oncology antibody drugs to activate the immune system against hard-to-treat cancers.
Sweden ATORX
Allogene Therapeutics, Inc. Logo
Developing off-the-shelf CAR T-cell therapies for cancer and autoimmune diseases.
United States of America ALLO
Israel KVSR
Almirall S.A. Logo
A global biopharmaceutical company developing innovative medical solutions for skin health.
Spain ALM
ALNYLAM PHARMACEUTICALS, INC. Logo
Pioneering RNAi gene-silencing therapies for rare genetic and cardiometabolic diseases.
United States of America ALNY

Talk to a Data Expert

Have a question? We'll get back to you promptly.